In MetS+ patients, beta-adrenergic receptor 1 (ADRB1) mRNA levels were increased (1.73-fold) in SAT, while ADRB3 levels were decreased (0.33-fold) in VAT. This evidence concerns the gene ADRB1 and metabolic syndrome.